Login to Your Account

'We are very confident in the science'

Sage comes up flat in SRSE phase III, but 'understanding' gained

By Marie Powers
News Editor

Wednesday, September 13, 2017

Sage Therapeutics Inc. sought to emphasize the lessons learned and increased understanding from the top-line readout of its first phase III trial, which assessed brexanolone (SAGE-547) in patients with super-refractory status epilepticus, or SRSE. The highly anticipated trial missed its primary endpoint of comparing the candidate's success in weaning of third-line agents and resolution of potentially life-threatening status epilepticus vs. placebo (43.9 percent vs. 42.4 percent; p=0.8775) when added to standard of care.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription